Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MDRX 
Veradigm Inc. (MDRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: MDRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.83
1 Year Target Price $5.83
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.72% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 510.42M USD | Price to earnings Ratio - | 1Y Target Price 5.83 |
Price to earnings Ratio - | 1Y Target Price 5.83 | ||
Volume (30-day avg) 3 | Beta 0.77 | 52 Weeks Range 3.00 - 11.80 | Updated Date 07/2/2025 |
52 Weeks Range 3.00 - 11.80 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -14.7% | Operating Margin (TTM) 16.59% |
Management Effectiveness
Return on Assets (TTM) -0.62% | Return on Equity (TTM) -1.69% |
Valuation
Trailing PE - | Forward PE 15.17 | Enterprise Value 283270000 | Price to Sales(TTM) 0.87 |
Enterprise Value 283270000 | Price to Sales(TTM) 0.87 | ||
Enterprise Value to Revenue 0.48 | Enterprise Value to EBITDA 4.85 | Shares Outstanding 108600000 | Shares Floating 81238736 |
Shares Outstanding 108600000 | Shares Floating 81238736 | ||
Percent Insiders 3.29 | Percent Institutions 41.97 |
Upturn AI SWOT
Veradigm Inc.
Company Overview
History and Background
Veradigm Inc., formerly known as Allscripts Healthcare Solutions, was founded in 1986. It evolved through mergers and acquisitions, including the merger of Medic Computer Systems and HCmS in 1997 and the acquisition of Misys Healthcare in 2008. The company rebranded to Veradigm in 2018 to reflect its focus on data and analytics.
Core Business Areas
- Provider Solutions: Offers electronic health records (EHR), practice management, and revenue cycle management solutions for healthcare providers.
- Payer Solutions: Provides solutions for payers, including data analytics, risk adjustment, and quality reporting.
- Data and Analytics Solutions: Offers data analytics and insights to improve healthcare outcomes and reduce costs.
Leadership and Structure
The CEO is Yin Ho. The organizational structure includes various departments responsible for product development, sales, marketing, finance, and operations.
Top Products and Market Share
Key Offerings
- Sunrise EHR: Comprehensive EHR platform used by hospitals and health systems. Epic and Cerner are competitors. Market share is estimated to be in the single digits.
- Professional EHR: EHR system designed for smaller physician practices. Competitors include athenahealth and eClinicalWorks. Market share is estimated to be in the low single digits.
- Veradigm Network: A health information network that connects payers, providers, and patients. Competitors include Carequality and CommonWell Health Alliance. No public market share data is available.
Market Dynamics
Industry Overview
The healthcare IT industry is experiencing growth driven by the need for digital transformation, data interoperability, and value-based care.
Positioning
Veradigm is positioned as a provider of integrated healthcare solutions, focusing on data-driven insights and improved clinical outcomes. Its competitive advantages lie in its extensive data network and established customer base.
Total Addressable Market (TAM)
The total addressable market for healthcare IT is estimated to be in the hundreds of billions of dollars. Veradigm is positioned to capture a portion of this market through its various product offerings. It is estimated the market is over $200 Billion. Veradigm is well positioned to take advantage of this vast market.
Upturn SWOT Analysis
Strengths
- Established customer base
- Extensive data network
- Integrated product portfolio
- Strong brand recognition
Weaknesses
- Integration challenges with acquired companies
- Dependence on EHR market
- Competition from larger players
- History of security breaches
Opportunities
- Expansion into new markets
- Development of new data analytics solutions
- Partnerships with other healthcare providers
- Adoption of cloud-based solutions
Threats
- Increased competition
- Changing regulatory landscape
- Data security breaches
- Economic downturn
Competitors and Market Share
Key Competitors
- CERN
- MTBC
- NXGN
Competitive Landscape
Veradigm faces strong competition from larger players like Cerner and smaller, more focused companies. Its strengths lie in its integrated product portfolio and established customer base, but it needs to address its integration challenges and data security concerns.
Major Acquisitions
Practice Fusion
- Year: 2018
- Acquisition Price (USD millions): 100
- Strategic Rationale: Expanded Veradigm's reach in the ambulatory EHR market and provided access to a large patient database.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been moderate, driven by acquisitions and organic growth in its core business segments.
Future Projections: Future growth is projected to be driven by demand for data analytics and value-based care solutions. Analyst estimates are difficult to assess given the ongoing SEC investigation.
Recent Initiatives: Recent initiatives include expanding its data network, developing new cloud-based solutions, and investing in data analytics capabilities.
Summary
Veradigm is a mid-sized healthcare IT company with a strong presence in the EHR and data analytics markets. While it has a valuable data network and established customer base, it faces challenges related to competition, integration, and data security. The ongoing SEC investigation adds significant uncertainty. The company needs to focus on addressing these challenges to maintain its competitive position and achieve sustainable growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (delayed due to SEC investigation)
- Industry reports
- Analyst estimates (limited due to SEC investigation)
- Public news sources
Disclaimers:
Financial data may be outdated due to the SEC investigation. Market share estimates are approximate and based on publicly available information. This analysis is for informational purposes only and should not be considered investment advice. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Veradigm Inc.
Exchange NASDAQ | Headquaters Chicago, IL, United States | ||
IPO Launch date 1999-07-26 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 2450 | Website https://veradigm.com |
Full time employees 2450 | Website https://veradigm.com | ||
Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising practice management software, AI patient scheduling software, and electronic statements and payments, and payerpath clearinghouse; revenue cycle services and coding services; electronic health records solutions, which include eprescribe with EPCS, EHR software, veradigm EHR, and practice fusion EHR; and patient engagement platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as veradigm connect, veradigm app expo, and diagnostic ordering and resulting network; life sciences, health plans and payers, and providers; and veradigm eprescribe enterprise. In addition, the company offers risk adjustment solutions, such as health equity analytics, risk adjustment analytics, risk mitigator, comprehensive submissions, and utilization analytics; quality analytics, risk adjustment, and quality management; data exchange and coding solutions, including echart courier, echart coder, and echart integration and analytics; clinical data registries for physicians and veradigm payer insights; provider engagement solutions; care gap alerting, gap closure services, and veradigm payerpath solutions. Further, it provides real world data solutions, such as NLP-enriched EHR data solutions, and clinical data registries; real world evidence and real-world evidence analytics platform; and digital health media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.